Welcome to our dedicated page for Autolus Therapeutics news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics stock.
Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Autolus Therapeutics (AUTL) has received FDA regenerative medicine advanced therapy (RMAT) designation for obecabtagene autoleucel (obe-cel) to treat systemic lupus erythematosus (SLE) and lupus nephritis (LN). RMAT status, created under the 21st Century Cures Act, is intended to accelerate development and regulatory review of regenerative medicines, including cell therapies, for serious or life‑threatening diseases.
The designation for obe-cel in SLE and LN is supported by Phase 1b data from the CARLYSLE trial and is expected, in the company’s view, to provide a framework for efficient development within the pivotal LUMINA trial. LUMINA, a Phase 2 study in patients with refractory lupus nephritis, is currently enrolling across five countries, with data expected in 2028. An additional data update from the Phase 1 CARLYSLE trial in SLE has been submitted for presentation at the American College of Rheumatology Annual Meeting in the fourth quarter of 2026.
Autolus Therapeutics (Nasdaq: AUTL) reported Q2 2026 net product revenue of $45.7 million from AUCATZYL, up 119% year-over-year and up from $26.2 million in Q1 2026. Total Q2 revenue was $45.7 million versus $20.9 million a year earlier.
Q2 2026 gross margin reached 55%, compared with 6% in Q1 2026 and negative margins in 2025, driven by higher volumes, lower manufacturing cost per batch and reduced inventory reserves. The company raised full-year 2026 AUCATZYL net product revenue guidance to $140–$150 million, from $120–$135 million.
Autolus entered a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors; $75 million was funded at close, with $25 million optionally available within six months and $150 million contingent on revenue milestones. Q2 2026 net loss narrowed to $39.1 million from $47.9 million, with loss from operations at $43.8 million versus $61.2 million. Cash, cash equivalents and marketable securities totaled $201.6 million at June 30, 2026, and Autolus expects to fund operations into Q2 2028.
Autolus Therapeutics (Nasdaq: AUTL) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST, with pre-registration required for dial-in details, and a live webcast plus replay available in the events section of the company’s website.
Autolus Therapeutics (Nasdaq: AUTL) reported preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and a year-to-date gross margin of about 35%. The company increased its full-year 2026 AUCATZYL sales guidance to $140–$150 million, up from prior guidance of $120–$135 million.
Autolus highlighted that Q2 2026 AUCATZYL sales grew about 70% versus Q1 2026 and more than 100% versus Q2 2025, supported by higher utilization at existing treatment centers and new centers coming online. Gross margin improved from roughly -20% in the second half of 2025 to about 35% in the first half of 2026.
The company also entered a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors. An initial $75 million tranche closed on July 30, 2026, with an additional $25 million available for up to six months and up to $150 million more contingent on revenue milestones. The facility bears interest at one-month SOFR (with a 3.50% floor) plus 7.25%. Autolus issued Perceptive a warrant to purchase up to 3.5 million ADSs at $1.9314 per ADS. The first two tranches, totaling $100 million, together with existing cash, are expected to fund operations into Q2 2028.
Autolus Therapeutics (Nasdaq: AUTL) granted equity awards under its 2025 Inducement Plan to 13 new employees, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards cover options for 25,420 ADSs at a $1.66 exercise price and 87,530 RSUs, with four-year vesting tied to continued service.
Autolus Therapeutics (Nasdaq: AUTL) will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Dr. Christian Itin will join a fireside chat on June 30, 2026 at 9:00am EDT / 14:00 BST.
The live webcast and a 90-day replay will be accessible via the company’s Investor Relations & Media Events webpage.
Autolus Therapeutics (Nasdaq: AUTL) announced it received the 2026 Prix Galien UK Award for Best Biotechnology Product. The award is presented by the Galien Foundation and selected by a 12-member UK Awards Committee of healthcare experts.
According to Autolus, the recognition reflects its mission to translate pioneering scientific research, developed with University College London, into new treatment options for patients, and highlights the dedication of its teams and their commitment to patients.
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor conferences in early June 2026. CEO Dr. Christian Itin will present at the William Blair 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, with live webcasts and 90-day replays.
Autolus Therapeutics (Nasdaq: AUTL) announced an abstract for the ASCO 2026 meeting reporting a post-hoc analysis of the Phase Ib/II FELIX study of obe-cel in adult relapsed/refractory B-ALL, including patients with extramedullary disease (EMD).
Of 127 obe-cel–infused patients, 27 (21%) had EMD at lymphodepletion. In patients with EMD, the overall remission rate was 59% and median duration of response was 42.6 months, supporting a favorable benefit–risk profile.
Autolus Therapeutics (Nasdaq: AUTL) reported Q1 2026 net product revenue of $26.2 million from AUCATZYL, up from $9.0 million a year earlier, and a positive gross profit of $1.6 million for its ALL business.
The UK launch began in January 2026. Autolus announced a cost-reduction plan, including a 13% workforce reduction expected to cut annual operating expenses by about $15 million from 2027, with roughly $8 million of restructuring charges. Net loss was $71.6 million, and cash, cash equivalents and marketable securities totaled $229.4 million, with runway projected into Q4 2027. Multiple obe-cel and AUTO8 trials are enrolling, with key data readouts expected from 2026 through 2028.